Valuation MINAPHARM Pharmaceuticals

Stocks

End-of-day quote Egyptian Exchange 01/10/2026			5-day change	1st Jan Change
812.49 ^EGP	+4.21%		+0.32%	+132.67%

27/08	CEPI backs Minapharm's experimental Ebola vaccine with up to $16.5 million funding	RE
27/08	Minapharm Group Receives Funding to Advance Bundibugyo Ebolavirus Vaccine Candidate to Clinical Trials	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Market Cap ¹	987	1,303	1,822	2,408	1,796	4,114
Change	-	32.02%	39.82%	32.19%	-25.41%	129.01%
Enterprise Value (EV) ¹	922	1,570	2,562	4,297	4,395	5,224
Change	-	70.23%	63.21%	67.74%	2.27%	18.88%
P/E	3.28x	2.91x	2.88x	-43.5x	14x	584x
PBR	0.64x	0.69x	0.55x	0.7x	0.44x	0.66x
PEG	-	0.1x	0.1x	0x	-0x	-6.2x
Capitalization / Revenue	0.42x	0.43x	0.5x	0.62x	0.32x	0.64x
EV / Revenue	0.39x	0.52x	0.71x	1.1x	0.78x	0.81x
EV / EBITDA	1.48x	1.89x	2.36x	8.02x	3.75x	3.87x
EV / EBIT	1.71x	2.1x	2.66x	11.5x	4.71x	5.13x
EV / FCF	3.33x	-10.9x	-4.11x	-3.25x	-10.3x	-28.5x
FCF Yield	30.1%	-9.18%	-24.3%	-30.7%	-9.71%	-3.51%
Dividend per Share ²	2.7	2.922	2.8	1.65	2.5	-
Rate of return	3.36%	2.76%	1.89%	0.76%	1.54%	-
EPS ²	24.47	36.42	51.41	-5.006	11.58	0.5979
Distribution rate	11%	8.02%	5.45%	-33%	21.6%	-
Net sales ¹	2,361	3,005	3,621	3,892	5,665	6,438
EBITDA ¹	621.7	828.5	1,086	536	1,172	1,348
EBIT ¹	538.8	746.5	964.7	374.7	933.8	1,019
Net income ¹	300.8	466.4	612.7	-31.99	157.1	40.22
Net Debt ¹	-65.01	266.5	739.6	1,889	2,598	1,110
Reference price ²	80.29	106.00	148.21	217.68	162.36	349.20
Nbr of stocks (in thousands)	12,293	12,293	12,293	11,064	11,064	11,781
Announcement Date	31/03/21	31/03/22	30/03/23	07/04/24	12/06/25	10/06/26

¹EGP in Million²EGP

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
MINAPHARM PHARMACEUTICALS	-	-	-	-	18Cr
ELI LILLY AND COMPANY	32.45x	11.78x	23.93x	0.61%	1,01900Cr
JOHNSON & JOHNSON	28.48x	6.32x	17.7x	2.09%	62TCr
ABBVIE INC.	33.26x	7.78x	16.08x	2.64%	46TCr
MERCK & CO., INC.	104.98x	5.87x	24.89x	2.36%	36TCr
ROCHE HOLDING AG	18.81x	4.58x	11.36x	2.9%	33TCr
NOVARTIS AG	19.83x	5.17x	12.78x	3.09%	27TCr
ASTRAZENECA PLC	20.02x	4.17x	11.86x	2.13%	24TCr
AMGEN INC.	25.46x	6.66x	11.86x	2.5%	22TCr
GILEAD SCIENCES, INC.	-43.78x	6.39x	24.97x	2.27%	18TCr
Average	26.61x	6.52x	17.27x	2.29%	36.97TCr
Weighted average by Cap.	31.80x	7.61x	18.61x	1.96%